View Author
scopus: 7101849940

Bladé, J.

(Joan Bladé)


patient myeloma bortezomib thalidomide dexamethasone study therapy treatment response lenalidomide trial blood phase combination survival regimen group neuropathy cancer result grade month disease university transplantation agent melphalan factor myeloma patients table cycle serum novel agents prednisone randomized signi cell transplantation hospital outcome cyclophosphamide doxorubicin analysis progression high-dose oncol novel signi ficantly ef ficacy hematology department richardson maintenance induction response rate pegylated liposomal doxorubicin protein number autologou incidence leukemia event reduction chain relapse j clin oncol effect celgene palumbo light chemotherapy marrow erasmus mc high-dose dexamethasone toxicity prognostic ficacy institute criteria induction therapy journal




10 Most Recent Publications

Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (Article)
Fernández De Larrea, C. Kyle, R. Kumar, S. Mahindra, A. Comenzo, R.L. Palumbo, A. Mazumber, A. Anderson, K.C. Richardson, P.G. Badros, A.Z. Caers, J. Cavo, M. Durie, B.G.M. Leleu, X. Dimopoulos, M.A. Chim, C.S. Schots, R. Noeul, A. Fantl, D. Mellqvist, U.H. Landgren, O. Chanan-Khan, A. Moreau, P. Ludwig, H. Fonseca, R. Merlini, G. Lahuerta, J.J. Bladé, J. Orlowski, R.Z. Shah, J.J. Usmani, S.M. Vesole, D. Hajek, R. San Miguel, J-F. Sezer, O. Sonneveld, P.
2013-04-01
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (Article)
Kumar, S. Lee, J.H. Leleu, X. Hulin, C. Klein, S.K. Sonneveld, P. Siegel, D. Bladé, J. Goldschmidt, H. Jagannath, S. Miguel, J.S. Orlowski, R.Z. Lahuerta, J.J. Palumbo, A. Sezer, O. Rajkumar, S.V. Durie, B.G.M. Morgan, G. Richardson, P.G. Crowley, J. Haessler, J. Feather, J. Hoering, A. Moreau, P.
2012-01-01
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN) (Article)
Palumbo, A. Bringhen, S. Zweegman, S. Terpos, E. Davies, F. Driessen, C. Gimsing, P. Gramatzki, M. Hajek, R. Johnsen, H.E. Da Costa, F.L. Sezer, O. Ludwig, H. Spencer, A. Beksaç, M. Morgan, G. Einsele, H. San Miguel, J. Sonneveld, P. Dimopoulos, M.A. Bladé, J. Mateos, M.V. Rosiñol, L. Boccadoro, M. Cavo, M. Lokhorst, H.M.
2011-10-27
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression (Article)
Shah, J. Bladé, J. Sonneveld, P. Harousseau, J-L. Lantz, K. Londhe, A. Lowery, C. Orlowski, R.Z.
2011-08-15
International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation (Article)
Cavo, M. Rajkumar, S.V. Sonneveld, P. Boccadoro, M. Anderson, K.C. Richardson, P.G. Bensinger, W. Johnsen, H.E. Kroeger, N. Gahrton, G. Bergsagel, P.L. Vesole, D.H. Palumbo, A. Einsele, H. Jagannath, S. Niesvizky, R. Durie, B.G.M. Miguel, J.S. Lonial, S. Moreau, P. Orlowski, R.Z. Bladé, J. Sezer, O. Ludwig, H. Dimopoulos, M.A. Attal, M.
2011-06-09
Treatment of relapsed and refractory multiple myeloma in the era of novel agents (Article)
Donk, N.W.C.J. van de Lokhorst, H.M. Goldschmidt, H. Sonneveld, P. Johnsen, H.E. Bladé, J. San-Miguel, J-F. Palumbo, A. Dimopoulos, M.A. Cavo, M. Morgan, G. Einsele, H. Kropff, M. Schey, S. Avet-Loiseau, H. Ludwig, H.
2011-06-01
Multiple myeloma treatment strategies with novel agents in 2011: A European perspective (Article)
Ludwig, H. Beksaç, M. Goldschmidt, H. Harousseau, J-L. Hess, U. Kropff, M. Da Costa, F.L. Louw, V. Magen-Nativ, H. Mendeleeva, L. Nahi, H. Plesner, T. Bladé, J. San Miguel, J. Sonneveld, P. Udvardy, M. Sondergeld, P. Palumbo, A. Cavenagh, J. Cavo, M. Delforge, M. Dimopoulos, M.A. Drach, J. Einsele, H. Facon, T.
2011-05-06
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues (Article)
Delforge, M. Bladé, J. Dimopoulos, M.A. Facon, T. Kropff, M. Ludwig, H. Palumbo, A. Damme, P. van San-Miguel, J-F. Sonneveld, P.
2010-11-01
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin (Article)
Buda, G. Ricci, D. Huang, C.C. Favis, R. Cohen, N. Zhuang, S.H. Harousseau, J-L. Sonneveld, P. Bladé, J. Orlowski, R.Z.
2010-11-01
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (Article)
Kyle, R. Durie, B.G.M. San Miguel, J-F. Avet-Loiseau, H. Hajek, R. Chen, W. Anderson, K.C. Ludwig, H. Sonneveld, P. Pavlovsky, S. Palumbo, A. Richardson, P.G. Rajkumar, S.V. Barlogie, B. Greipp, P. Vescio, R. Turesson, I. Westin, J. Boccadoro, M. Landgren, O. Bladé, J. Merlini, G. Kröger, N. Einsele, H. Vesole, D. Dimopoulos, M.A.
2010-04-22
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile